Clinical trials
Squamous Cell Lung Cancer clinical trials
Below are recruiting squamous cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 680 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06357533RecruitingPhase 3
New drug combo for advanced lung cancer with high PD-L1
This trial tests a new two-drug combination (Dato-DXd and an immunotherapy called rilvegostomig) as the first treatment for people with advanced non-squamous lung cancer who have high PD-L1 levels. The goal is to see if this combination works better than current standard options.
Anchorage, AlaskaAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT06809764Recruiting
Study of T-DXd in Chinese patients with HER2m NSCLC
This study looks at how safe and effective the drug T-DXd (trastuzumab deruxtecan) is for Chinese patients with a specific type of lung cancer that has a HER2 mutation. It helps understand if this treatment works well in real-world settings.
BeijingAges 18 years+ - NCT06768307RecruitingPhase 2
Adebrelimab + Chemo with Radiation for Extensive-Stage SCLC
This study tests whether giving a combination of the immunotherapy drug Adebrelimab plus chemotherapy together with radiation (given at the same time) is better than giving radiation after chemo for people with extensive-stage small cell lung cancer who haven't been treated before.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06865339RecruitingPhase 2
Radiation plus immunotherapy for advanced lung cancer
This trial tests whether adding two immunotherapy drugs (cemiplimab and fianlimab) to standard radiation and chemotherapy can help treat locally advanced non-small cell lung cancer that hasn't been treated before.
The Bronx, New YorkAges 18 years+ - NCT06179069RecruitingPhase 1
Study of ZL-1310 for small cell lung cancer
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Duarte, CaliforniaAges 18 years+ - NCT06125041RecruitingPhase 2
Adebelizumab with chemo and radiation for advanced lung cancer
This trial tests a new drug called Adebelizumab (an immunotherapy) combined with chemotherapy and radiation for people with extensive stage small cell lung cancer. The goal is to see if this combination helps shrink tumors and improves survival.
Jinan, ShandongAges 18–75 - NCT05778253Recruiting
Blood and AI pathology to guide treatment in resectable lung cancer
This study checks whether special blood testing plus computer-based review of tumor slides can help plan care for lung squamous cell cancer that can be removed by surgery. It looks at patients who have not had prior cancer treatment and who meet specific stage and health criteria.
Changsha, HunanAges 18–75 - NCT05382728RecruitingPhase 3
Test drug for EGFR-mutant lung cancer without prior treatment
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
Changsha, HunanAges 18–80 - NCT05394831RecruitingPhase 1/Phase 2
Study of an EGFR-targeted drug for advanced lung cancer
This trial tests a new drug (JIN-A02) in people with advanced or metastatic non-small cell lung cancer (NSCLC) whose cancer has specific EGFR mutations. It mainly checks whether the treatment is safe and tolerable, and how the body handles the drug, with possible benefit depending on your mutation type.
Orange, CaliforniaAges 18 years+ - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT06911606RecruitingPhase 2
Serplulimab with chemotherapy before surgery for limited-stage small cell lung cancer
This trial tests adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery for limited-stage small cell lung cancer (LS-SCLC). The goal is to see if this combination helps shrink the tumor and improve outcomes for patients who have not received prior treatment.
Guangzhou, GuangdongAges 18–75 - NCT07559786RecruitingPhase 2
Adebrelimab after chemo-radiation for limited-stage small cell lung cancer
This trial tests whether the drug adebrelimab (a type of immunotherapy) can help prevent your lung cancer from coming back after you finish chemotherapy and radiation. It is for people with limited-stage small cell lung cancer (cancer found only in one lung and nearby lymph nodes) that did not grow during initial treatment.
Zhengzhou, HenanAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for bone metastases from advanced lung cancer
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07198217RecruitingPhase 2
Chemo, radiation, and immunotherapy for lung cancer
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Zibo, ShandongAges 18–75 - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07217301RecruitingPhase 3
Comparing TAK-928 to docetaxel for advanced lung cancer
This study tests a new drug called TAK-928 against the standard chemo docetaxel for people with advanced squamous non-small cell lung cancer. You may be able to join if you have already tried a checkpoint inhibitor and platinum chemotherapy, and your cancer has grown.
Jonesboro, ArkansasAges 18 years+ - NCT07322783RecruitingPhase 2
Osimertinib plus savolitinib for resistant lung cancer
This trial tests a combination of two targeted drugs (osimertinib and savolitinib) for people with a specific type of advanced non-small cell lung cancer that has stopped responding to standard treatments. It may help patients whose cancer has a low number of MET gene copies.
QingdaoAges 18–80 - NCT06306456RecruitingPhase 1/Phase 2
GH21 combined with osimertinib for advanced lung cancer
This trial tests a new drug (GH21) combined with the targeted therapy osimertinib (Tagrisso) for people with advanced non-small cell lung cancer that has an EGFR mutation and has stopped responding to a similar treatment. The goal is to see if the combination can help when the cancer has progressed.
Hefei, AnhuiAges 18 years+ - NCT05745350RecruitingPhase 2
First treatment for extensive-stage small cell lung cancer
This trial studies how well pembrolizumab, plinabulin, and etoposide plus platinum work as first treatment for extensive-stage small cell lung cancer. It may help some people by boosting the immune response while also attacking cancer with standard chemotherapy.
Wuhan, HubeiAges 18 years+ - NCT06668103RecruitingPhase 2
Study of ABSK043 and Firmonertinib for EGFR-mutant lung cancer
This study tests a new combination of two targeted therapies (ABSK043 and firmonertinib) for people with a specific type of advanced lung cancer. It is for patients whose tumors have an EGFR mutation and are PD-L1 positive.
Hefei, AnhuiAges 18 years+ - NCT05668650RecruitingPhase 3
Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Viedma, Río Negro ProvinceAges 18 years+ - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT07181499RecruitingPhase 2
Chemotherapy with befotertinib for resistance to targeted lung cancer drugs
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
Guangzhou, GuangdongAges 18 years+
Hear when a new Squamous Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for squamous cell lung cancer?
- Yes. Clin2 currently lists 680 recruiting squamous cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a squamous cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a squamous cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Squamous Cell Non-small Cell Lung Cancer
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Squamous Non-small-cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.